blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4005575

EP4005575 - APPLICATION OF TANNIC ACID IN PREPARATION OF ANTI-RESPIRATORY VIRUS DRUG [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  22.09.2023
Database last updated on 04.06.2024
FormerRequest for examination was made
Status updated on  29.04.2022
FormerThe international publication has been made
Status updated on  25.02.2022
Formerunknown
Status updated on  18.02.2022
Most recent event   Tooltip19.04.2024New entry: Despatch of examination report + time limit 
Applicant(s)For all designated states
Suntrap Life Technologies Ltd.
N°22 Longrong Road
Hualong Town Panyu District
Guangzhou
Guangdong 511434 / CN
[2022/22]
Inventor(s)01 / FU, Jun
Guangdong 511434 / CN
 [2022/22]
Representative(s)Petraz, Gilberto Luigi, et al
GLP S.r.l.
Viale Europa Unita, 171
33100 Udine / IT
[2022/22]
Application number, filing date20948896.410.09.2020
[2022/22]
WO2020CN114432
Priority number, dateCN20201082658617.08.2020         Original published format: CN202010826586
[2022/22]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022036774
Date:24.02.2022
Language:ZH
[2022/08]
Type: A1 Application with search report 
No.:EP4005575
Date:01.06.2022
Language:EN
[2022/22]
Search report(s)International search report - published on:CN24.02.2022
(Supplementary) European search report - dispatched on:EP09.11.2022
ClassificationIPC:A61K31/7024, A61K33/00, A61K33/06, A61K33/26, A61K33/30, A23K20/24, A23K50/20, A23K50/40, A23K50/50, A23K50/75, A23L33/10, A61P31/14, A23K50/30
[2022/49]
CPC:
A61P31/14 (EP,CN,US); A61K31/7024 (EP,CN); A61K31/7034 (US);
A23K20/163 (CN); A23K20/24 (EP); A23K50/20 (EP,CN);
A23K50/30 (EP,CN); A23K50/40 (EP,CN); A23K50/50 (EP,CN);
A23K50/70 (CN); A23K50/75 (EP); A23L33/10 (EP,CN);
A61K31/05 (US); A61K31/353 (US); A61K33/00 (EP);
A61K33/06 (EP,US); A61K33/24 (US); A61K33/26 (EP,US);
A61K33/30 (EP,US); A61K9/0053 (US); A61K9/12 (US);
A23V2002/00 (CN) (-)
C-Set:
A61K31/7024, A61K2300/00 (EP);
A61K33/00, A61K2300/00 (EP);
A61K33/06, A61K2300/00 (EP);
A61K33/26, A61K2300/00 (EP);
A61K33/30, A61K2300/00 (EP);
A23V2002/00, A23V2200/30 (CN)
(-)
Former IPC [2022/22]A61K31/7024
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/22]
TitleGerman:VERWENDUNG VON GERBSÄURE BEI DER HERSTELLUNG EINES MEDIKAMENTS GEGEN ATEMWEGSVIREN[2022/22]
English:APPLICATION OF TANNIC ACID IN PREPARATION OF ANTI-RESPIRATORY VIRUS DRUG[2022/22]
French:APPLICATION D'ACIDE TANNIQUE DANS LA PRÉPARATION DE MÉDICAMENT ANTI-VIRUS RESPIRATOIRES[2022/22]
Entry into regional phase17.02.2022Translation filed 
17.02.2022National basic fee paid 
17.02.2022Search fee paid 
17.02.2022Designation fee(s) paid 
17.02.2022Examination fee paid 
Examination procedure17.02.2022Examination requested  [2022/22]
07.06.2023Amendment by applicant (claims and/or description)
07.06.2023Date on which the examining division has become responsible
26.09.2023Despatch of a communication from the examining division (Time limit: M04)
02.02.2024Reply to a communication from the examining division
18.04.2024Despatch of a communication from the examining division (Time limit: M04)
Fees paidRenewal fee
06.07.2022Renewal fee patent year 03
17.08.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2009098786  (MOCHIGASE CO LTD [JP], et al) [Y] 2-7 * in particular * * paragraphs [0019] , [0 22] , [0 23] , [0 30] , [0 31] * * claims * * the whole document *;
 [Y]WO2010111644  (PULMATRIX INC [US], et al) [Y] 2-7 * in particular * * 'Summary' ** Claims; paragraphs [0017] , [0 29] , [ 111] , [ 113] *;
 [IY]WO2019055312  (INTRAMONT TECH INC [US]) [I] 2-7 * the whole document * * in particular * * paragraph [0004] - paragraph [0007] * * paragraphs [0009] , [0010] , [0 15] , [0 17] - [0019] - [0 24] * * Claims * [Y] 2-7;
 [E]WO2020186258  (INTRAMONT TECH INC [US]) [E] 1-6 * the whole document * * in particular * * paragraphs [0004] - [0009] * * paragraph [0017] - paragraph [0022] * * paragraph [0027] * * 'Embodiments of the invention include:' * * Examples * * paragraph [0032] - paragraph [0035] * * Claims * * claims 20, 21, 27, 28 *;
 [E]WO2021155864  (SYNEURX INT TAIWAN CORP [CN]) [E] 1-3 * the whole document * * in particular * * page 49, line 18 - page 50, line 15 * * p. 59 et seqq. * * III. Applications of Composition of Formula I * * page 63, line 14 - line 26 * * Examples * * Claims * * in particular also claim 32 *;
 [E]WO2021207399  (SYTHEON LTD [US]) [E] 1 * the whole document * * in particular * * 'Summary' * * paragraph [0045] * * paragraph [0060] - paragraph [0085] * * Examples * * Claims *;
 [XY]  - Kouhpayeh Shirin ET AL, "The Molecular Story of COVID-19; NAD+ Depletion Addresses All Questions in this Infection", doi:10.20944/preprints202003.0346.v1, (20200323), URL: https://pdfs.semanticscholar.org/789b/8739d51c2ff2fb3cbb00aa01f49363ecf6e8.pdf?_ga=2.91754899.867626919.1637587836-712076082.1637587836, (20211122), XP055864283 [X] 1 * in particular * * page 13 * * 3.5 Tannins * [Y] 2-7

DOI:   http://dx.doi.org/10.20944/preprints202003.0346.v1
 [IY]  - Hospital De Clinicas Jos� De San Mart�n, "Tannin Specific Natural Extract for COVID-19 Infection (TanCOVID) NCT04403646", Clinical Trials, (20200527), URL: https://clinicaltrials.gov/ct2/show/NCT04403646, (20210708), XP055822477 [I] 1 * the whole document * [Y] 2-7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.